Duchenne Muscular Dystrophy: Second Product Isn't The Charm
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA reviewers say patients treated with Sarepta's eteplirsen seemed to follow similar disease course as Duchenne muscular dystrophy natural history, casting doubts on product's approvability.